JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

NCT07714304 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Harboring EGFR Mutations

Interventions

DRUG: JS212 for Injection
DRUG: JS111 capsules (AP-L1898)

Sponsor

Huan Zhou